388 related articles for article (PubMed ID: 7641380)
1. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots.
Prager NA; Abendschein DR; McKenzie CR; Eisenberg PR
Circulation; 1995 Aug; 92(4):962-7. PubMed ID: 7641380
[TBL] [Abstract][Full Text] [Related]
2. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa.
McKenzie CR; Abendschein DR; Eisenberg PR
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1285-91. PubMed ID: 8857926
[TBL] [Abstract][Full Text] [Related]
3. Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
Eisenberg PR; Siegel JE; Abendschein DR; Miletich JP
J Clin Invest; 1993 May; 91(5):1877-83. PubMed ID: 8486759
[TBL] [Abstract][Full Text] [Related]
4. Procoagulant activity on injured arteries and associated thrombi is mediated primarily by the complex of tissue factor and factor VIIa.
Speidel CM; Thornton JD; Meng YY; Eisenberg PR; Edgington TS; Abendschein DR
Coron Artery Dis; 1996 Jan; 7(1):57-62. PubMed ID: 8773434
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of local inhibition of procoagulant activity associated with small-diameter prosthetic vascular grafts.
Oltrona L; Eisenberg PR; Abendschein DR; Rubin BG
J Vasc Surg; 1996 Oct; 24(4):624-31. PubMed ID: 8911411
[TBL] [Abstract][Full Text] [Related]
7. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
[TBL] [Abstract][Full Text] [Related]
8. Effect of SanOrg123781A, a synthetic hexadecasaccharide, on clot-bound thrombin and factor Xa in vitro and in vivo.
Hérault JP; Cappelle M; Bernat A; Millet L; Bono F; Schaeffer P; Herbert JM
J Thromb Haemost; 2003 Sep; 1(9):1959-65. PubMed ID: 12941037
[TBL] [Abstract][Full Text] [Related]
9. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors.
Weitz JI; Leslie B; Hudoba M
Circulation; 1998 Feb; 97(6):544-52. PubMed ID: 9494024
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis.
Nicolini FA; Lee P; Malycky JL; Lefkovits J; Kottke-Marchant K; Plow EF; Topol EJ
Blood Coagul Fibrinolysis; 1996 Jan; 7(1):39-48. PubMed ID: 8845461
[TBL] [Abstract][Full Text] [Related]
11. Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood.
Eisenberg PR; Miletich JP
Thromb Res; 1989 Sep; 55(5):635-43. PubMed ID: 2510363
[TBL] [Abstract][Full Text] [Related]
12. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
Meddahi S; Samama MM
Blood Coagul Fibrinolysis; 2009 Apr; 20(3):207-14. PubMed ID: 19657318
[TBL] [Abstract][Full Text] [Related]
13. Effect of hirudin on tissue plasminogen activator induced clot lysis.
Electricwala A; Atkinson T
Blood Coagul Fibrinolysis; 1990 Aug; 1(3):267-71. PubMed ID: 2129413
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma.
Gast A; Tschopp TB; Schmid G; Hilpert K; Ackermann J
Blood Coagul Fibrinolysis; 1994 Dec; 5(6):879-87. PubMed ID: 7893925
[TBL] [Abstract][Full Text] [Related]
15. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
[TBL] [Abstract][Full Text] [Related]
16. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis.
Orvim U; Barstad RM; Vlasuk GP; Sakariassen KS
Arterioscler Thromb Vasc Biol; 1995 Dec; 15(12):2188-94. PubMed ID: 7489241
[TBL] [Abstract][Full Text] [Related]
17. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J
Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336
[TBL] [Abstract][Full Text] [Related]
18. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits.
Speidel CM; Eisenberg PR; Ruf W; Edgington TS; Abendschein DR
Circulation; 1995 Dec; 92(11):3323-30. PubMed ID: 7586321
[TBL] [Abstract][Full Text] [Related]
19. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
[TBL] [Abstract][Full Text] [Related]
20. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity.
Urano T; Nagai N; Matsuura M; Ihara H; Takada Y; Takada A
Thromb Haemost; 1998 Jul; 80(1):161-6. PubMed ID: 9684803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
